All Podcasts – Lifestyle
Author:
Allarity Therapeutics, Inc.
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
May 8, 2026
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
May 5, 2026
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
April 27, 2026
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
April 21, 2026
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
March 31, 2026
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
March 6, 2026